Ulcavis pills 120 mg 28 pcs
Condition: New product
995 Items
Rating:
Be the first to write a review!
More info
Active ingredients
Bismuth tri-potassium dicitrate
Release form
Pills
Composition
Active ingredient: bismuth tri-potassium dicitrate 303.03 mg (equivalent to bismuth oxide 120 mg) excipients: corn starch - 72.17 mg; Povidone K30 - 18 mg; policrilin potassium - 23.8 mg; macrogol 6000 - 6 mg; magnesium stearate - 2 mg membrane film: Opadry II transparent (polyvinyl alcohol - 4.505 mg, macrogol 4000 - 2.295 mg; talc - 1.7 mg) - 8.5 mg; titanium dioxide (E171) - 1.5 mg
Pharmacological effect
Anti-ulcer, gastroprotective, anti-helicobacter
Pharmacokinetics
Bismuth subcitrate is practically not absorbed from the gastrointestinal tract. Excreted mainly through the intestines with feces. An insignificant amount of bismuth entering the blood plasma is excreted by the kidneys.
Indications
Peptic ulcer and duodenal ulcer in the acute phase, including associated with Helicobacter pylori; chronic gastritis and gastroduodenitis in the acute phase, incl. associated with Helicobacter pylori; irritable bowel syndrome, occurring predominantly with diarrhea symptoms; functional dyspepsia, not associated with organic diseases of the gastrointestinal tract
Contraindications
Individual intolerance to the drug; severe renal impairment (Cl creatinine less than 30 ml / min); pregnancy; breastfeeding period; children up to 4 years
Use during pregnancy and lactation
The use of the drug Ulcavis during pregnancy and during breastfeeding is contraindicated
Dosage and administration
Inside, 30 minutes before a meal, with a small amount of water. Adults and children over 12 years old, Ulcavis, is prescribed 1 tab. 4 times a day 30 minutes before meals and at night or 2 tab. 2 times a day. Children from 8 to 12 years old drug Ulcavis prescribed 1 tab. 2 times a day; from 4 to 8 years prescribed at a dose of 8 mg / kg / day, depending on the body weight of the child, 1-2 pills / day (respectively, in 1-2 doses per day). In this case, the daily dose should be closest to the calculated dose (8 mg / kg / day). Duration of treatment 4-8 weeks. Over the next 8 weeks. do not use bismuth-containing drugs. For the eradication of Helicobacter pylori, it is advisable to use the drug Ulcavis in combination with other antibacterial agents with anti-helicobacter activity (as recommended by the doctor).
Side effects
On the part of the digestive system: possible nausea, vomiting, more frequent stools, constipation. These phenomena are not dangerous to health and are temporary.Allergic reactions: skin rash, pruritus. With prolonged use in high doses may develop encephalopathy associated with the accumulation of bismuth in the central nervous system
Overdose
Symptoms: dyspepsia, skin rash, inflammation of the oral mucosa, characteristic darkening in the form of blue lines on the gums. An overdose of the drug Ulcavis, caused by prolonged doses higher than recommended, may lead to impaired renal function. These symptoms are completely reversible with discontinuation of the drug Ulcavis. Treatment: gastric lavage, the appointment of activated carbon and saline laxatives. Further treatment should be symptomatic. In the event of impaired renal function, which is accompanied by a high concentration of bismuth in the blood plasma, chelation agents (penicillamine, sodium dimercaptopropanesulfonate) can be administered. In the case of pronounced renal impairment, hemodialysis is indicated.
Interaction with other drugs
Within half an hour before and after taking Ulcavis, the use of other drugs, as well as the ingestion of food and liquids, in particular, antacids, milk, fruit and fruit juices, is not recommended. This is due to the fact that they, while ingesting, can influence the effectiveness of Ulcavis. The simultaneous use of the drug Ulcavis with tetracycline reduces the absorption of the latter
special instructions
Ulcavis should not be used for more than 8 weeks. It is also not recommended during treatment to exceed the prescribed daily doses for adults and children. During the period of treatment with Ulcavis, do not use other medicines containing bismuth. At the end of the course of treatment with the drug in recommended doses, the concentration of the active substance in the blood plasma does not exceed 3–58 mcg / l, and intoxication is observed only when the concentration in the blood plasma is higher than 100 mcg / l. When using the drug Ulcavis, it is possible to stain feces in a dark color due to the formation of bismuth sulfide. Sometimes there is a slight darkening of the tongue.